Free tool
FAERS Monitor: Cyanokit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022041 or its brand name (Cyanokit, Hydroxocobalamin). Reports on generic versions are filed under their own applications.
Reports
4,238
Serious
3,876
91% of reports
Hospitalization
1,664
Death reported
315
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- acute kidney injury211
- nausea207
- diarrhoea205
- dyspnoea190
- dizziness178
- vomiting167
- off label use166
- malaise151
- hyponatraemia138
- fatigue136
- confusional state129
- rash120
- pruritus114
- somnolence114
- drug ineffective113
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 11 |
| 2007 | 19 |
| 2008 | 42 |
| 2009 | 32 |
| 2010 | 32 |
| 2011 | 77 |
| 2012 | 85 |
| 2013 | 98 |
| 2014 | 149 |
| 2015 | 152 |
| 2016 | 218 |
| 2017 | 252 |
| 2018 | 346 |
| 2019 | 393 |
| 2020 | 377 |
| 2021 | 278 |
| 2022 | 320 |
| 2023 | 350 |
| 2024 | 368 |
| 2025 | 305 |
| 2026 | 319 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,921 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyponatraemiaSignal | 138 | 12.2 | 10.3 | 1,407 |
| acute kidney injurySignal | 211 | 6.9 | 6.0 | 1,055 |
| confusional stateSignal | 129 | 4.0 | 3.3 | 285 |
| somnolenceSignal | 114 | 2.8 | 2.3 | 132 |
| dizziness | 178 | 1.8 | 1.5 | 60 |
| vomiting | 167 | 1.8 | 1.5 | 56 |
| malaise | 151 | 1.7 | 1.5 | 45 |
| dyspnoea | 190 | 1.7 | 1.4 | 51 |
| diarrhoea | 205 | 1.6 | 1.4 | 44 |
| pruritus | 114 | 1.5 | 1.2 | 17 |
| rash | 120 | 1.4 | 1.1 | 12 |
| nausea | 207 | 1.3 | 1.1 | 14 |
| off label use | 166 | 0.9 | 0.8 | 1 |
| fatigue | 136 | 0.9 | 0.7 | 3 |
| drug ineffective | 113 | 0.4 | 0.4 | 93 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.